(Press-News.org) The CLINICAL24 campaign will see SelectScience partner with a variety of organisations, clinical laboratories and industry brands, to raise awareness of the role of clinical professionals, and those who support them.
As part of the partnership, both organisations will share updates and content of interest to their audiences and AMI will supply speakers for SelectScience’s upcoming Clinical Summit in March 2025.
Global interdisciplinary community
AMI nurtures and engages a global interdisciplinary community, providing opportunities for collaboration, making advancements in, and through, applied microbiology.
“We fundamentally believe that global challenges need to be solved by global, interdisciplinary experts who apply their diverse experience and unique voices to achieve a common goal. Because of this we are a truly inclusive, international organisation,” AMI chief executive Dr Lucy Harper said.
“We bring the microbiology community together across borders and disciplines, we look to the future and nurture those working and studying in our field, and we enable meaningful collaboration to advance scientific impact.
“We are delighted to team up with SelectScience, bringing our members together with other scientists and manufacturers, and we believe this collaboration will be very valuable to all.”
Connecting communities
SelectScience’s mission is to accelerate science by connecting scientific communities with trusted technology solutions.
The online publisher informs scientists and healthcare professionals about the latest technology and lab products, through the power of peer-to-peer recommendation, and by partnering with product, technology and service suppliers to engage with scientists’ feedback.
SelectScience’s latest initiative, CLINICAL24, is a global media campaign designed to promote conversation across borders about the latest challenges facing clinical laboratories, and exploring the technology solutions to overcome them.
Peer-to-peer conversation
“SelectScience believes that uniting communities and encouraging peer-to-peer conversation, advances science and healthcare. This is why we are delighted to be partnering with AMI, with the shared goal of facilitating knowledge sharing,” says Sonia Nicholas, SelectScience’s Managing Editor and Clinical Lead.
“In October, SelectScience will host CLINICAL24, a conversation designed to cross borders with the goal of sharing knowledge and experience between healthcare systems. We are excited to collaborate with AMI on this feature, to hear from experienced professionals in both of our communities about their current challenges and the use of technology to overcome them.”
To find out more about partnering with AMI, email josie@appliedmicrobiology.org.
To participate in #CLINICAL24 become a SelectScience member.
Notes to editors
Applied Microbiology International (AMI) is the oldest microbiology society in the UK and with more than half of its membership outside the UK, is truly global, serving microbiologists based in universities, private industry and research institutes around the world.
AMI provides funding to encourage research and broad participation at its events and to ensure diverse voices are around the table working together to solve the sustainability development goals it has chosen to support.
AMI publishes leading industry magazine, The Microbiologist, and in partnership with Oxford University Press, publishes three internationally acclaimed journals. It gives a voice to applied microbiologists around the world, amplifying their collective influence and informing international, evidence-based, decision making. END
Applied Microbiology International teams up with SelectScience
2024-09-16
ELSE PRESS RELEASES FROM THIS DATE:
Montefiore Einstein Comprehensive Cancer Center establishes new immunotherapy institute
2024-09-16
September 16, 2024—(BRONX, NY)— The National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has announced the new Marilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders. Xingxing Zang, Ph.D., an international leader in developing novel immunotherapies, has been named its inaugural director.
“Our goal is to be at the forefront of developing novel immunotherapy technologies and advancing them into ...
New research solves Crystal Palace mystery
2024-09-16
New research has answered the mystery of how the Crystal Palace in London, which at the time was the world’s largest building, was constructed in only 190 days.
The study, led by Professor John Gardner of Anglia Ruskin University (ARU) in Cambridge, England, has discovered that the Crystal Palace was the first building known to have made use of a standard screw thread – something that’s now taken for granted in modern construction and engineering.
Completed just in time for the start ...
Shedding light on superconducting disorder
2024-09-16
The importance of disorder in physics is only matched by the difficulty to study it. For example, the remarkable properties of high-temperature superconductors are greatly affected by variations in the chemical composition of the solid. Techniques that enable measurements of such disorder and its impact on the electronic properties, such as scanning tunnelling microscopy, work only at very low temperatures, and are blind to these physics near the transition temperature. Now, a team of researchers of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) in Germany and Brookhaven National ...
Setting the stage for the “Frankfurt Alliance”
2024-09-16
FRANKFURT. In January 2024, 16 Frankfurt-based research institutions joined forces to set up the “Frankfurt Alliance”, made up of Goethe University Frankfurt and several non-university research institutions. With the aim of visualizing at an event held in the heart of the Main metropolis both the strength and the diversity of research conducted in the science city of Frankfurt and the larger Rhine-Main region, including its importance for society, the alliance invites you to the first “Science Festival”, held
on Saturday, September 28, from 10 a.m. to 7 p.m.
at Roßmarkt
in ...
Alliance presents final results from phase III CABINET pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors at ESMO 2024 and published in New England Journal of Medicine
2024-09-16
The Alliance for Clinical Trials in Oncology today announced final results will be presented at ESMO 2024 from CABINET (A021602), a phase III trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET). The study met the primary objective for each cohort, demonstrating that cabozantinib provided dramatic improvements in median ...
X.J. Meng receives prestigious MERIT Award to study hepatitis E virus
2024-09-16
To build upon a quarter-century of world-renowned research in zoonotic viral diseases, X.J. Meng has been rewarded with a prestigious National Institutes of Health (NIH) Method to Extend Research in Time (MERIT) Award – the first awarded to Virginia Tech.
“This is a huge honor and privilege,” said Meng, University Distinguished Professor of Molecular Virology in the Virginia-Maryland College of Veterinary Medicine and a member of the National Academy of Sciences. “It is really gratifying to know ...
Wyss Institute team selected to develop first-of-its-kind biologically engineered broad-spectrum antimicrobial therapeutic under a contract from the DARPA-SHIELD program
2024-09-16
By Benjamin Boettner
(BOSTON) — Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard Universityreceived a contract for up to $12M from the Defense Advanced Research Projects Agency (DARPA)’s new SHIELD program. The SHIELD (Synthetic Hemo-technologies to Locate and Disinfect) program aims to develop a prophylactic treatment that can be broadly administered to trauma victims in combat casualty care scenarios to rapidly clear multiple bloodborne bacterial and fungal pathogens, limit morbidity and mortality, and protect recipients for up to seven days.
Blood ...
‘Food theft’ among seabirds could be transmission point for deadly avian flu
2024-09-16
The deadly H5N1 avian influenza virus, which has killed millions of birds worldwide since 2021 – and in rare cases can be transmitted to humans – may be spread through the food-stealing behaviour of some seabirds.
A study published today in the journal Conservation Letters highlights food theft – also known as ‘kleptoparasitism’, where some seabird species like frigatebirds and skuas force other birds to regurgitate their prey – as a possible transmission path for the spread of avian flu.
Led by scientists from UNSW Sydney’s ...
SwRI and UTSA developing helmet pads to reduce traumatic brain injury in military service members
2024-09-16
SAN ANTONIO — September 16, 2024 —Researchers from Southwest Research Institute (SwRI) and The University of Texas at San Antonio (UTSA) are creating innovative military helmet pads designed to prevent traumatic brain injury (TBI). The project, led by SwRI’s Dr. Daniel Portillo and UTSA’s Dr. Morteza Seidi, is supported by a $125,000 grant from the Connecting through Research Partnerships (Connect) program.
Traumatic brain injury can affect human performance and quality of life. It is ...
Waiting is the hardest part: Medical field should address uncertainty for cancer patients under active surveillance
2024-09-16
Indianapolis – Patients with low-risk cancers undergoing active surveillance face a favorable long-term prognosis. David Haggstrom, M.D., MAS, makes the case that it’s time for the medical field to help manage the anxiety caused by waiting.
Dr. Haggstrom, a physician-researcher with Regenstrief Institute, the Veterans Administration Medical Center in Indianapolis and the Indiana University School of Medicine, is lead author of a Viewpoint article, published in JAMA (Journal of the American Medical ...